SCHEMBL5221227

SCHEMBL5221227

Clc1ccc2c(c1)CCC2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.64
HTR2C P28335 1/20 0.64
HTR2B P41595 1/20 0.64
PNMT P11086 1/20 0.54
KDM1A O60341 3/20 0.47
ALDH1A1 P00352 2/20 0.45
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
POLB P06746 1/20 0.42
METAP1 P53582 1/20 0.41
HTT P42858 1/20 0.41
F7 P08709 1/20 0.39
PARP1 P09874 1/20 0.39
F3 P13726 1/20 0.39
PARP10 Q53GL7 1/20 0.39
TSHR P16473 1/20 0.39
GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30218134 1.00 HTR2A (0.64) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL29724224 0.95 HTR2A (0.64) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL5496769 0.95 HTR2A (0.64) HTR2AHTR2CHTR2BPNMTKDM1A
Hydrochloric Acid SCHEMBL27261560 0.92 HTR2A (0.61) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL15962624 0.89
SCHEMBL23188936 0.89 HTR2A (0.53) HTR2AHTR2CHTR2BPNMTKDM1A
Ammonia Solution, Strong SCHEMBL10465265 0.86 HTR2A (0.67) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL5143608 0.81 HTR2A (0.46) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL12430509 0.81 HTR2A (0.46) HTR2AHTR2CHTR2BPNMTKDM1A
SCHEMBL16559360 0.79 HTR2A (0.58) HTR2AHTR2CHTR2BPNMTKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118895515-A Application of platinum carbon catalyst-loaded electrode in aryl compound benzyl carbon-hydrogen bond oxidation reaction 南京航空航天大学 2024-11-05 CN claimed
CN-119118881-B Guanidine-containing 5-chloroindane compound, and preparation method and application thereof 中国农业大学 2026-01-02 CN disclosed
CN-119118881-B Guanidine-containing 5-chloroindane compound, and preparation method and application thereof 中国农业大学 2026-01-02 CN disclosed
CN-119118881-A Guanidine-containing 5-chloroindane compound, and preparation method and application thereof 中国农业大学 2024-12-13 CN disclosed
CN-119118881-A Guanidine-containing 5-chloroindane compound, and preparation method and application thereof 中国农业大学 2024-12-13 CN disclosed
CN-119118881-A Guanidine-containing 5-chloroindane compound, and preparation method and application thereof 中国农业大学 2024-12-13 CN disclosed
CN-118895515-A Application of platinum carbon catalyst-loaded electrode in aryl compound benzyl carbon-hydrogen bond oxidation reaction 南京航空航天大学 2024-11-05 CN disclosed
CN-118591521-A Process for preparing 5-chloro-2, 3-dihydro-1H-inden-1-one 安道麦马克西姆有限公司 2024-09-03 CN disclosed
CN-118591521-A Process for preparing 5-chloro-2, 3-dihydro-1H-inden-1-one 安道麦马克西姆有限公司 2024-09-03 CN disclosed
EP-4392410-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS FOR USE AS THERAPEUTICS The University of British Columbia (CA) 2024-07-03 EP disclosed
EP-1660427-A4 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2006-12-20 EP disclosed
US-20060178366-A1 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION 2006-08-10 US disclosed
EP-1660427-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2006-05-31 EP disclosed
WO-2005123724-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY DECODE CHEMISTRY, INC. (US) 2005-12-29 WO disclosed
EP-1603887-A1 HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES Tibotec Pharmaceuticals Ltd. (IE) 2005-12-14 EP disclosed
WO-2005016862-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORPORATION (JP) 2005-02-24 WO disclosed
WO-2004074261-A1 HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2004-09-02 WO disclosed
EP-0063418-B1 INDANYLOXY- AND TETRALINYLOXY-PHENOXYPROPIONIC ACID DERIVATIVES, PROCESSES FOR PREPARING THEM, AND HERBICIDAL PROCESSES AND COMPOSITIONS UTILISING THEM IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-10-03 EP disclosed
US-4431834-A INDAN OR TETRALIN DERIVATIVES; PLANT GROWTH REGULATORS; GRASSES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-02-14 US disclosed
EP-0063418-A1 Indanyloxy- and tetralinyloxy-phenoxypropionic acid derivatives, processes for preparing them, and herbicidal processes and compositions utilising them IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178366-A1 Compounds for the treatment of inflammatory disorders MMP12, ADAMTS1, TNF HTR2A 4340/4885HTR2C 4579/4885HTR2B 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.